Thomas S Uldrick

18PUBLICATIONS
83CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 01, 2025
Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.

Denise M Connolly, Gabriel Revon-Rivière, Rose Chami

|Apr 04, 2025
Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda.

Manoj P Menon, Henry Ddungu, Kelvin R Mubiru

|Feb 06, 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.

Ramya Ramaswami, Angela Shaulov Kask, Leonard D'Amico

|Dec 09, 2024
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.

Min Zhu, Priyanka Madia, Alison Crawford

|Oct 02, 2024
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

Kathryn Lurain, Ramya Ramaswami, Irene Ekwede

|Nov 07, 2023
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer.

Thomas A Odeny, Kathryn Lurain, Julius Strauss

Pageof 3

Frequent Collaborators

6 joint publications

Kathryn Lurain

5 joint publications

Ramya Ramaswami

4 joint publications

Robert Yarchoan

3 joint publications

Caroline Schenkel